Invicta Diagnostic P/E Ratio
Current P/E Ratio
20.3
Moderate Valuation
High - Growth expectations or overvalued
Invicta Diagnostic P/E ratio. Invicta Diagnostic (INVICTA) P/E ratio is 20.3 (Moderate), EPS (TTM) ₹4.90, current price ₹ on None — High - Growth expectations or overvalued. For live price, revenue and the complete fundamental profile, see INVICTA share price.
Current Valuation Metrics
P/E Ratio
20.3
Current Price
₹
EPS (TTM)
₹4.90
Exchange
None
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
52.34
Sector Median
29.6
Sector Rank
#11 of 255
Sector Percentile
4.3%
INVICTA P/E Ratio — Valuation Signal & Historical Context
Invicta Diagnostic P/E 20.3 — signal: Overvalued. Also explore INVICTA share price charts to track price trends across different timeframes.
- Trading at discount to sector average PE of 52.34
INVICTA vs Healthcare Peers — P/E Ratio Comparison
Invicta Diagnostic P/E 20.3 vs Healthcare average 52.34, median 29.6 — range 2.0–733.0.
Sector Average
52.34
Sector Median
29.6
Lowest P/E
2.0
Highest P/E
733.0
Companies
255
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.0 | ₹72 | Low |
| Brooks Laboratories | BROOKS | 2.6 | ₹206 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.3 | ₹54 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.1 | ₹6,355 | Low |
| Dipna Pharmachem | DPL | 4.5 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 4.7 | ₹82 | Low |
| Royal Sense | ROYAL | 4.8 | ₹34 | Low |
| Star Imaging And Path Lab | STARIMAGIN | 5.3 | ₹110 | Low |
| Kabra Drugs | KABRADG | 6.3 | ₹49 | Low |